Jake Jorgovan

NOVEMBER 29, 2023

The Value of a Biopharma Consulting Firm Beyond mere compliance, these consultants offer strategic vision. BioPharma Consultants : Specializes in marketing, strategy, and corporate development services for the biotech and pharmaceutical industries, offering solutions from product launch plans to commercial support for fundraising.

Biopharmaceuticals 130

Biopharmaceuticals Biopharma Biotech Life science 130

Frost & Sullivan

APRIL 25, 2023

years, to become a truly global company with a diverse mix of public sector and biopharma clients. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world. Christine Dingivan said, “This award recognizes the efforts of everyone who works at Emmes.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

Frost & Sullivan

JULY 22, 2021

Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).

Biotech 98

Biotech Biopharmaceuticals Biotechnology Government 98

IBM Business Partners

MAY 20, 2024

Quantum computing is a new kind of computer processing technology that relies on the science that governs the behavior of atoms to solve problems that are too complex or not practical for today’s fastest supercomputers. For example, Moderna has been pioneering the development of quantum for biotechnology.

Biotech 100

Biotech Biopharma Biotechnology Life science 100

Frost & Sullivan

APRIL 3, 2024

Simtra BioPharma Solutions announced over $250 million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana. FUJIFILM Diosynth Biotechnologies invested $1.6 AbbVie introduced a customized risk-based governance model for agile and compliant operations in a highly regulated and risk-sensitive environment.

Biopharmaceuticals 59

Biopharmaceuticals Biopharma Biotechnology Life science 59

LaVoie Health Science Blog

JULY 16, 2021

Paul Sagan, Vice President of Investor Relations and Corporate Communications, discusses the growing investment case for ESG reporting within the biotechnology field, the unique challenges of developing an ESG approach in the life sciences, and the important considerations posed by potential new SEC recommendations and international ESG standards.

Life science 69

Life science Biopharma Biotech Biotechnology 69